TherapeuticsMD, Inc. (TXMD)
NASDAQ: TXMD · Real-Time Price · USD
2.100
+0.030 (1.45%)
At close: Apr 28, 2026, 4:00 PM EDT
2.100
0.00 (0.00%)
After-hours: Apr 28, 2026, 6:13 PM EDT
TherapeuticsMD Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 3.02 | 1.76 | 1.3 | 69.96 | 2.57 | Upgrade
|
| Revenue Growth (YoY) | 71.61% | 35.25% | -98.14% | 2619.12% | -96.03% | Upgrade
|
| Cost of Revenue | - | - | - | 1.4 | 1.4 | Upgrade
|
| Gross Profit | 3.02 | 1.76 | 1.3 | 68.57 | 1.17 | Upgrade
|
| Selling, General & Admin | 5.01 | 4.74 | 8.9 | 56.71 | 72.75 | Upgrade
|
| Operating Expenses | 5.39 | 5.25 | 9.83 | 57.9 | 72.75 | Upgrade
|
| Operating Income | -2.37 | -3.49 | -8.52 | 10.66 | -71.58 | Upgrade
|
| Interest & Investment Income | 0.14 | 0.14 | - | - | - | Upgrade
|
| Other Non Operating Income (Expenses) | 1.75 | 2.28 | 0.78 | -0.12 | 0.27 | Upgrade
|
| EBT Excluding Unusual Items | -0.48 | -1.08 | -7.74 | 10.55 | -71.31 | Upgrade
|
| Merger & Restructuring Charges | - | - | - | -9.47 | - | Upgrade
|
| Asset Writedown | -0.18 | -1.27 | - | - | - | Upgrade
|
| Other Unusual Items | - | - | - | - | -8 | Upgrade
|
| Pretax Income | -0.65 | -2.34 | -7.74 | 1.07 | -79.31 | Upgrade
|
| Income Tax Expense | - | -0.03 | -0.04 | - | - | Upgrade
|
| Earnings From Continuing Operations | -0.65 | -2.31 | -7.7 | 1.07 | -79.31 | Upgrade
|
| Earnings From Discontinued Operations | 0.08 | 0.13 | -2.58 | 110.92 | -93.11 | Upgrade
|
| Net Income | -0.57 | -2.18 | -10.28 | 112 | -172.42 | Upgrade
|
| Net Income to Common | -0.57 | -2.18 | -10.28 | 112 | -172.42 | Upgrade
|
| Shares Outstanding (Basic) | 12 | 12 | 10 | 9 | 8 | Upgrade
|
| Shares Outstanding (Diluted) | 12 | 12 | 10 | 9 | 8 | Upgrade
|
| Shares Change (YoY) | 0.32% | 10.45% | 11.48% | 17.66% | 44.39% | Upgrade
|
| EPS (Basic) | -0.05 | -0.19 | -0.98 | 12.41 | -21.66 | Upgrade
|
| EPS (Diluted) | -0.05 | -0.19 | -0.99 | 11.95 | -21.66 | Upgrade
|
| Free Cash Flow | 2.42 | 0.73 | -48.14 | -4.08 | -142.73 | Upgrade
|
| Free Cash Flow Per Share | 0.21 | 0.06 | -4.61 | -0.43 | -17.93 | Upgrade
|
| Gross Margin | 100.00% | 100.00% | 100.00% | 98.00% | 45.51% | Upgrade
|
| Operating Margin | -78.33% | -198.30% | -654.61% | 15.24% | -2781.85% | Upgrade
|
| Profit Margin | -18.83% | -123.85% | -789.40% | 160.08% | -6700.93% | Upgrade
|
| Free Cash Flow Margin | 80.21% | 41.57% | -3697.46% | -5.83% | -5547.10% | Upgrade
|
| EBITDA | -1.98 | -2.98 | -8.08 | 11.86 | -70.84 | Upgrade
|
| EBITDA Margin | -65.62% | -169.39% | - | 16.95% | - | Upgrade
|
| D&A For EBITDA | 0.38 | 0.51 | 0.44 | 1.19 | 0.74 | Upgrade
|
| EBIT | -2.37 | -3.49 | -8.52 | 10.66 | -71.58 | Upgrade
|
| EBIT Margin | -78.33% | -198.30% | - | 15.24% | - | Upgrade
|
| Revenue as Reported | - | - | - | 69.96 | 2.57 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.